Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
verteporfin · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| I | EXPERIMENTAL | Combined treatment with verteporfin (Visudyne) and ranibizumab (Lucentis) |
| II | EXPERIMENTAL | Treatment with ranibizumab (Lucentis) |
| Name | Type | Description |
|---|---|---|
| verteporfin (Visudyne) | DRUG | Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1 |
| ranibizumab (Lucentis) | DRUG | ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33\&37 per study protocol |
Inclusion Criteria: * All previously untreated CNV secondary to MD
Verteporfin is an investigational small molecule being studied for the treatment of Choroidal Neovascularization, a condition associated with macular degeneration. It is in Phase 1 clinical development for this ophthalmic indication.
Verteporfin is a small molecule used in photodynamic therapy. It is activated by light to produce a therapeutic effect on abnormal blood vessels in the eye, specifically targeting Choroidal Neovascularization.
Verteporfin is being developed by Atlantic International Corp., a company traded under the ticker ATLN. The company is conducting clinical trials to evaluate the drug for Choroidal Neovascularization.
Verteporfin is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial has been completed to assess its safety and efficacy.
Verteporfin has one completed clinical trial, NCT00570193, titled 'Photodynamic and Pharmacologic Treatment of CNV'. This Phase 1 study enrolled 41 participants with Choroidal Neovascularization and Macular Degeneration.
Verteporfin is the generic name for the drug also known as Visudyne. It is being studied for Choroidal Neovascularization, and the completed trial NCT00570193 evaluated its use in this condition.